Liposomes

PreclinicalSmall molecule

KKenneth Peters, MD

Liposomes is one of 75 small molecule programs targeting Interstitial Cystitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisActive, not recruiting

CystitisActive, not recruiting

Interstitial CystitisPreclinical

Active, not recruiting

CystitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Interstitial Cystitis

#DrugCompanyPhaseTrials

Revia

Pitocin

1 3

Myrbetriq

Astellas

Phase 3

1 4

Cimzia

UCB

Phase 3

1 5

Xolair

Roche

Phase 3

1 6

Intron a

Sanofi

Phase 3

1 7

Humira

CCelltrion

Phase 3

1 8

Sodium Hyaluronate

Sanofi

Phase 3

1 9

Neoral

Novartis

Phase 2

1 10

Ajovy

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystitis1 trial

Intravesical Liposomes for Ulcerative Cystitis

Completed·KKenneth Peters, MD·N/A·NCT01083979·1 enrolled

Interstitial Cystitis1 trial

Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

Completed·KKenneth Peters, MD·N/A·NCT01731470·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Liposomes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kenneth Peters, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKenneth Peters, MD

Liposomes

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystitis1 trial

Interstitial Cystitis1 trial

References

Drug Info

Quick Facts

Related News